BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the many 11 Greatest Genomics Shares to Purchase Based on Hedge Funds. Gena Wang of Barclays saved BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Purchase ranking with a worth goal of $86.00 in a report revealed on June 10.
A pharmaceutical plant manufacturing a proprietary artificial oral type of a C-type natriuretic peptide.
Based on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s most up-to-date earnings report, the agency made $745.15 million in income and $185.69 million in web revenue for the quarter that ended on March 31. The corporate’s gross sales had been $648.83 million, and its web revenue was $88.66 million final 12 months.
It’s difficult to keep away from previous comparisons with Genzyme (purchased by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Regardless of having a number of licensed therapies, the agency spent years within the pink because of commercialization and R&D prices, however analysts are optimistic concerning the long-term, worthwhile potential of its current portfolio. It’s in a powerful place due to its in depth inside pipeline and capability so as to add enlargement via strategic acquisitions.
Whereas we acknowledge the potential of BMRN as an funding, we consider sure AI shares provide better upside potential and carry much less draw back threat. If you happen to’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Excessive-Development EV Shares to Make investments In and 13 Greatest Automotive Shares to Purchase in 2025.
Disclosure. None.